Compugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call Transcript

Anat Cohen-Dayag: So totally, the latter, the latter. So AstraZeneca has the right to use the COM902 segment in their bispecifics. So they got the rights to develop bispecific based on our COM902. We own COM902. We also kept to ourselves right for certain bispecifics that we have an interest in. So for example, the TIGIT PVRIG or TIGIT PVRL2 with our COM902 is our — we do — we totally relate to COM902 as an asset. It’s nice to say that you noted that you mentioned the Fc question, which we were always saying, always that its either do not matter — does not matter or that if it matters, then it should be a silent one. And we’re happy to see that there is data now supporting it. We own COM701 and COM902. We believe that these are good partnering opportunities.

We have our own plans to move ahead with these assets internally, obviously, in a data-driven manner, in a biology-driven manner. But we do think that these are drug assets that can generate collaboration opportunities for us. And we will intend to proceed because we believe that with partners, we can broadly test them. And as — I answered today, but I think that one of the key things that should be mentioned. We tested COM701, COM902 combination in the most hard-to-treat patient populations. It gives us an edge. You can test it in single-arm studies, but one cannot ignore that these assets have a potential in the inflamed tumor type and this is a great opportunity based on the data that we have and the data that we have supporting COM701 driven effect, we believe that it could serve as good partnering opportunities.

And hopefully the TIGIT data that is out there and that will be out there by the companies that are leading this field will allow us to clear the air for TIGIT at least to understand that there is a benefit by adding TIGIT to PD-1 and that there is a third component that is needed. And I think that the world starts to say that there is a third component that is needed and we believe that it’s PVRIG. So, yes, on partnering front, that’s how we think about it.

Stephen Willey: Okay. Thanks for taking the questions.

Anat Cohen-Dayag: Thank you.

Operator: This concludes the Q&A session and Compugen’s Investor Conference Call. Thank you for your participation. You may go ahead and disconnect.